Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

[ad_1] Resources prioritized to advance avexitide in hyperinsulinemic hypoglycemia indications Phase 3 LIMT-2 study of peginterferon lambda in chronic hepatitis delta discontinued due to safety findings Company’s cash runway expected…

Wuxi Biologics Unit’s Hong Kong IPO Closes Order Book a Day Early, Sources Say

[ad_1] A unit of Chinese contract drugmaker Wuxi Biologics closed its order book a day early for its initial public offering and is likely to price the deal at the…

Wuxi Biologics Unit Plans to Raise $470.5 Million in Hong Kong IPO

[ad_1] A Wuxi Biologics unit plans to raise up to 3.68 billion Hong Kong dollars (US$470.5 million) through an initial public offering in one of Asia’s biggest stock markets. Wuxi…

Elevate Your Leadership Skills in Pharma: Agile Leadership Training for Professionals (March 7-8, 2024)

[ad_1] Dublin, Oct. 31, 2023 (GLOBE NEWSWIRE) — The “Agile Leadership for Pharma and Biopharma Professionals in a hybrid world Training Course” conference has been added to ResearchAndMarkets.com’s offering. Working…

Roche to Buy Bowel-Disease Drug From Roivant, Pfizer for More Than $7 Billion

[ad_1] Updated Oct. 23, 2023 6:55 am ET Roche Holding has agreed to buy the developer of a bowel-disease treatment from Roivant Sciences, a company started by Republican presidential candidate…

Bristol Myers Squibb to Acquire Mirati Therapeutics in Deal Worth Up to $5.8 Billion

[ad_1] The deal expands the pharmaceutical company’s portfolio of cancer drugs. [ad_2] Source link

Amgen Could Get a Piece of the Obesity Market

[ad_1] Amgen has a couple of shots on goal to break into one of the biggest markets the pharmaceutical industry has ever seen. [ad_2] Source link

WSJ News Exclusive | The Hedge Fund That Made a Killing Betting Against Lina Khan

[ad_1] Pentwater Capital predicted that FTC efforts to block big deals would fail. [ad_2] Source link

Blockbuster Cancer Treatment Stymied by Supply Chain—for Now

[ad_1] A cell therapy for multiple myeloma promises to be a major blockbuster for J&J and partner Legend, if they can increase manufacturing. [ad_2] Source link

Biden FTC’s Antitrust Bark Proves Worse Than Its Bite

[ad_1] The FTC settlement with Amgen will pave the way for more healthcare deal making. [ad_2] Source link